Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Business

FDA officially authorizes Zyn nicotine pouches for sale following health review

by admin January 18, 2025
January 18, 2025
FDA officially authorizes Zyn nicotine pouches for sale following health review

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Capital One outage drags into Friday afternoon, leaving some customers without deposit access
next post
UnitedHealth CEO says U.S. health system ‘needs to function better’

Related Posts

Boeing, NASA say Starliner astronaut launch will move...

May 26, 2024

Mortgage rates plunge to the lowest level in...

August 6, 2024

What the Ticketmaster-Live Nation lawsuit could mean for...

May 25, 2024

Is it time to rethink the 4% retirement...

May 15, 2024

Why Honeywell CEO Vimal Kapur doesn’t think the...

October 15, 2024

Bad economic news has been good for stocks,...

June 7, 2024

Home Depot is buying GMS for about $4.3...

July 1, 2025

Lululemon shares drop 15% as CEO says inflation,...

March 29, 2025

Government workers dismayed by Trump’s return-to-office mandate

January 27, 2025

Walmart, Chipotle and others feel the heat over...

July 10, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Tech Stocks Lead the Charge: What’s Driving the Momentum?

      July 2, 2025
    • S&P 500 Earnings for 2025 Q1 — Still Overvalued

      July 2, 2025
    • Top 10 July 2025 Stock Picks You Shouldn’t Miss

      July 2, 2025
    • House kicks off final sprint for Trump’s ‘big beautiful bill’ with key committee hearing

      July 2, 2025
    • Why Justice Jackson is a fish out of water on the Supreme Court

      July 2, 2025

    Categories

    • Business (1,007)
    • Investing (2,514)
    • Politics (3,125)
    • Stocks (1,110)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved